Lipofundin-Induced Hyperlipidemia Promotes Oxidative Stress and Atherosclerotic Lesions in New Zealand White Rabbits
Atherosclerosis represents a major cause of death in the world. It is known that Lipofundin 20% induces atherosclerotic lesions in rabbits, but its effects on serum lipids behaviour and redox environment have not been addressed. In this study, New Zealand rabbits were treated with 2 mL/kg of Lipofundin for 8 days. Then, redox biomarkers and serum lipids were determined spectrophotometrically. On the other hand, the development of atherosclerotic lesions was confirmed by eosin/hematoxylin staining and electron microscopy. At the end of the experiment, total cholesterol, triglycerides, cholesterol-LDL, and cholesterol-HDL levels were significantly increased. Also, a high index of biomolecules damage, a disruption of both enzymatic and nonenzymatic defenses, and a reduction of nitric oxide were observed. Our data demonstrated that Lipofundin 20% induces hyperlipidemia, which promotes an oxidative stress state. Due to the importance of these phenomena as risk factors for atherogenesis, we suggest that Lipofundin induces atherosclerosis mainly through these mechanisms..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2012 |
|---|---|
| Enthalten in: |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Livan Delgado Roche [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1155/2012/898769 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ006053769 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ006053769 | ||
| 003 | DE-627 | ||
| 005 | 20230309195423.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1155/2012/898769 |2 doi | |
| 035 | |a (DE-627)DOAJ006053769 | ||
| 035 | |a (DE-599)DOAJ7f9b896f0dfc4c4ea54182a2c208a1e8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC666-701 | |
| 100 | 0 | |a Livan Delgado Roche |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipofundin-Induced Hyperlipidemia Promotes Oxidative Stress and Atherosclerotic Lesions in New Zealand White Rabbits |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Atherosclerosis represents a major cause of death in the world. It is known that Lipofundin 20% induces atherosclerotic lesions in rabbits, but its effects on serum lipids behaviour and redox environment have not been addressed. In this study, New Zealand rabbits were treated with 2 mL/kg of Lipofundin for 8 days. Then, redox biomarkers and serum lipids were determined spectrophotometrically. On the other hand, the development of atherosclerotic lesions was confirmed by eosin/hematoxylin staining and electron microscopy. At the end of the experiment, total cholesterol, triglycerides, cholesterol-LDL, and cholesterol-HDL levels were significantly increased. Also, a high index of biomolecules damage, a disruption of both enzymatic and nonenzymatic defenses, and a reduction of nitric oxide were observed. Our data demonstrated that Lipofundin 20% induces hyperlipidemia, which promotes an oxidative stress state. Due to the importance of these phenomena as risk factors for atherogenesis, we suggest that Lipofundin induces atherosclerosis mainly through these mechanisms. | ||
| 653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
| 700 | 0 | |a Emilio Acosta Medina |e verfasserin |4 aut | |
| 700 | 0 | |a Ángela Fraga Pérez |e verfasserin |4 aut | |
| 700 | 0 | |a María A. Bécquer Viart |e verfasserin |4 aut | |
| 700 | 0 | |a Yosdel Soto López |e verfasserin |4 aut | |
| 700 | 0 | |a Viviana Falcón Cama |e verfasserin |4 aut | |
| 700 | 0 | |a Ana M. Vázquez López |e verfasserin |4 aut | |
| 700 | 0 | |a Gregorio Martínez-Sánchez |e verfasserin |4 aut | |
| 700 | 0 | |a Eduardo Fernández-Sánchez |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Vascular Medicine |d Hindawi Limited, 2010 |g (2012) |w (DE-627)DOAJ000039861 |x 20902832 |7 nnns |
| 773 | 1 | 8 | |g year:2012 |
| 856 | 4 | 0 | |u https://doi.org/10.1155/2012/898769 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/7f9b896f0dfc4c4ea54182a2c208a1e8 |z kostenfrei |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1155/2012/898769 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2090-2824 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2090-2832 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2012 | ||